MA39155A1 - Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol - Google Patents
Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérolInfo
- Publication number
- MA39155A1 MA39155A1 MA39155A MA39155A MA39155A1 MA 39155 A1 MA39155 A1 MA 39155A1 MA 39155 A MA39155 A MA 39155A MA 39155 A MA39155 A MA 39155A MA 39155 A1 MA39155 A1 MA 39155A1
- Authority
- MA
- Morocco
- Prior art keywords
- formoterol
- combination
- glycopyrronium bromide
- aerosol solution
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M2039/226—Spindles or actuating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une composition de solution d'aérosol, conçue pour être utilisée avec un aérosol-doseur mis sous pression, comportant du bromure de glycopyrronium et du formotérol, ou un sel de ceux-ci ou un solvate dudit sel, facultativement en combinaison avec un ou plusieurs principes actifs supplémentaires, stabilisée par une quantité choisie d'un acide minéral, la quantité de produit de dégradation n-(3-bromo)-[2-hydroxy-5-[l-hydroxy-2-[l-(4- méthoxyphényl) propan-2-ylamino]éthyl] phényl] formamide étant inférieure à la limite de quantification, lorsqu'elle est stockée dans des conditions accélérées à 25 °c et à une humidité relative (rh) de 60 % pendant 6 mois dans une boîte recouverte intérieurement par une résine comportant un polymère d'éthylène-propylène fluoré (fep). Le ou les principes actifs facultatifs peuvent être un corticostéroïde d'inhalation choisi parmi le dipropionate de béclométasone, le budésonide ou son épimère 22r, le ciclésonide, le flunisolide, le propionate de fluticasone, le furoate de fluticasone, le furoate de mométasone, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199784 | 2013-12-30 | ||
| PCT/EP2014/079259 WO2015101576A1 (fr) | 2013-12-30 | 2014-12-23 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39155A1 true MA39155A1 (fr) | 2017-04-28 |
Family
ID=49886777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39155A MA39155A1 (fr) | 2013-12-30 | 2016-06-28 | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10596113B2 (fr) |
| EP (3) | EP3089735B1 (fr) |
| JP (2) | JP6563950B2 (fr) |
| KR (2) | KR101861119B1 (fr) |
| CN (2) | CN105848641B (fr) |
| AR (1) | AR098982A1 (fr) |
| AU (1) | AU2014375301B2 (fr) |
| BR (1) | BR112016014583B1 (fr) |
| CA (1) | CA2935305C (fr) |
| CL (1) | CL2016001653A1 (fr) |
| CY (1) | CY1120668T1 (fr) |
| DK (1) | DK3089735T3 (fr) |
| EA (1) | EA033227B1 (fr) |
| ES (1) | ES2687345T3 (fr) |
| HK (1) | HK1225313A1 (fr) |
| HR (1) | HRP20181551T1 (fr) |
| HU (1) | HUE039513T2 (fr) |
| IL (1) | IL246498B (fr) |
| LT (1) | LT3089735T (fr) |
| MA (1) | MA39155A1 (fr) |
| MX (1) | MX368835B (fr) |
| MY (1) | MY182861A (fr) |
| PE (1) | PE20160997A1 (fr) |
| PH (1) | PH12016501268B1 (fr) |
| PL (1) | PL3089735T3 (fr) |
| PT (1) | PT3089735T (fr) |
| RS (1) | RS57687B1 (fr) |
| SA (1) | SA516371427B1 (fr) |
| SG (1) | SG11201605311UA (fr) |
| SI (1) | SI3089735T1 (fr) |
| TN (1) | TN2016000261A1 (fr) |
| TW (1) | TWI660747B (fr) |
| UA (1) | UA117845C2 (fr) |
| WO (1) | WO2015101576A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5914354B2 (ja) | 2009-12-23 | 2016-05-11 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Ｃｏｐｄ用併用療法 |
| ES2464520T3 (es) | 2009-12-23 | 2014-06-03 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| RU2561052C2 (ru) * | 2009-12-23 | 2015-08-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Комбинированное лечение хронического обструктивного заболевания легких |
| LT3089735T (lt) * | 2013-12-30 | 2018-09-10 | Chiesi Farmaceutici S.P.A. | Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija |
| MY176191A (en) * | 2013-12-30 | 2020-07-24 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| BR112018011266B1 (pt) | 2015-12-04 | 2023-11-21 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| CA3037092C (fr) * | 2016-09-19 | 2022-06-21 | Mexichem Fluor S.A. De C.V. | Compositions pharmaceutiques stables comprenant du glycopyrrolate et du 1,1-difluoroethane (hfa 152a) pour utilisation dans des aerosols-doseurs |
| CN107233311B (zh) * | 2017-06-27 | 2020-12-04 | 长风药业股份有限公司 | 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法 |
| WO2020084549A1 (fr) * | 2018-10-25 | 2020-04-30 | Glenmark Specialty S.A. | Composition de nébulisation comprenant du glycopyrrolate et du formotérol |
| WO2021009572A1 (fr) * | 2019-07-12 | 2021-01-21 | Kindeva Drug Delivery L.P. | Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation |
| WO2021110239A1 (fr) | 2019-12-02 | 2021-06-10 | Chiesi Farmaceutici S.P.A. | Boîte en acier inoxydable pour inhalateurs doseurs sous pression |
| WO2021151857A1 (fr) | 2020-01-28 | 2021-08-05 | Chiesi Farmaceutici S.P.A. | Inhalateurs doseurs sous pression comprenant une formulation pharmaceutique tamponnée |
| GB2593970B (en) | 2020-02-20 | 2024-09-04 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| CA3186956A1 (fr) | 2020-07-31 | 2022-02-03 | Chemo Research , S.L. | Polytherapie destinee a une administration par inhalation |
| CN112051346A (zh) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
| CN116419749A (zh) | 2020-10-09 | 2023-07-11 | 奇斯药制品公司 | 用于加压定量吸入器的药物制剂 |
| CN118475343A (zh) * | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
| WO2023227782A1 (fr) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique pour aérosol-doseur pressurisé |
| WO2023227781A1 (fr) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
| WO2023227783A1 (fr) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique pour aérosol-doseur sous pression |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| NZ509489A (en) | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| EP1241113A1 (fr) * | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient |
| EP1321159A1 (fr) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| RU2438660C2 (ru) | 2004-02-06 | 2012-01-10 | Меда Фарма Гмбх Унд Ко. Кг | Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей |
| NZ548300A (en) | 2004-02-06 | 2010-04-30 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| CN100457087C (zh) * | 2004-02-27 | 2009-02-04 | 奇斯药制品公司 | 用于加压计量吸入器的稳定的药用溶液制剂 |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| CA2565747A1 (fr) * | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Produits de formulation d'aerosol medicinale a stabilite chimique amelioree |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1879620A2 (fr) | 2005-03-30 | 2008-01-23 | Schering Corporation | Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EP2201934A1 (fr) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée |
| US20110132355A1 (en) * | 2009-06-09 | 2011-06-09 | William Gerhart | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| RU2561052C2 (ru) | 2009-12-23 | 2015-08-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Комбинированное лечение хронического обструктивного заболевания легких |
| ES2464520T3 (es) * | 2009-12-23 | 2014-06-03 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| JP5914354B2 (ja) * | 2009-12-23 | 2016-05-11 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Ｃｏｐｄ用併用療法 |
| ES2467928T3 (es) | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| EP2613828B1 (fr) | 2010-09-06 | 2019-11-27 | CHIESI FARMACEUTICI S.p.A. | Actionneur d'inhalateur de dose mesurée, inhalateur de dose mesurée |
| BR112013029507A2 (pt) * | 2011-05-17 | 2019-09-24 | Pearl Therapeutics Inc | método para tratar uma doença ou um distúrbio |
| BR112015002757A2 (pt) | 2012-08-29 | 2017-07-04 | Chiesi Farm Spa | acionador para dispositivo inalador de aerossol, objeto em forma cilíndrica oca, inalador, acionador de inalador dosimétrico, kit e uso de um acionador |
| LT3089735T (lt) * | 2013-12-30 | 2018-09-10 | Chiesi Farmaceutici S.P.A. | Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija |
| MY176191A (en) * | 2013-12-30 | 2020-07-24 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
-
2014
- 2014-12-23 LT LTEP14825154.9T patent/LT3089735T/lt unknown
- 2014-12-23 CN CN201480071526.7A patent/CN105848641B/zh active Active
- 2014-12-23 MY MYPI2016001207A patent/MY182861A/en unknown
- 2014-12-23 ES ES14825154.9T patent/ES2687345T3/es active Active
- 2014-12-23 DK DK14825154.9T patent/DK3089735T3/en active
- 2014-12-23 WO PCT/EP2014/079259 patent/WO2015101576A1/fr active Application Filing
- 2014-12-23 EP EP14825154.9A patent/EP3089735B1/fr active Active
- 2014-12-23 PL PL14825154T patent/PL3089735T3/pl unknown
- 2014-12-23 KR KR1020187007444A patent/KR101861119B1/ko active IP Right Grant
- 2014-12-23 PE PE2016000968A patent/PE20160997A1/es unknown
- 2014-12-23 CN CN202010180583.6A patent/CN111150728B/zh active Active
- 2014-12-23 EA EA201691126A patent/EA033227B1/ru active Protection Beyond IP Right Term
- 2014-12-23 EP EP19175726.9A patent/EP3566694A1/fr active Pending
- 2014-12-23 AU AU2014375301A patent/AU2014375301B2/en active Active
- 2014-12-23 PT PT14825154T patent/PT3089735T/pt unknown
- 2014-12-23 JP JP2016561079A patent/JP6563950B2/ja active Active
- 2014-12-23 TN TN2016000261A patent/TN2016000261A1/en unknown
- 2014-12-23 KR KR1020167020695A patent/KR101861117B1/ko active IP Right Grant
- 2014-12-23 UA UAA201606910A patent/UA117845C2/uk unknown
- 2014-12-23 BR BR112016014583-6A patent/BR112016014583B1/pt active IP Right Grant
- 2014-12-23 MX MX2016008594A patent/MX368835B/es active IP Right Grant
- 2014-12-23 SG SG11201605311UA patent/SG11201605311UA/en unknown
- 2014-12-23 CA CA2935305A patent/CA2935305C/fr active Active
- 2014-12-23 RS RS20181112A patent/RS57687B1/sr unknown
- 2014-12-23 SI SI201430881T patent/SI3089735T1/sl unknown
- 2014-12-23 EP EP18171127.6A patent/EP3384898A1/fr active Pending
- 2014-12-23 HU HUE14825154A patent/HUE039513T2/hu unknown
- 2014-12-29 AR ARP140104938A patent/AR098982A1/es not_active Application Discontinuation
- 2014-12-29 TW TW103146043A patent/TWI660747B/zh active
- 2014-12-30 US US14/585,533 patent/US10596113B2/en active Active
-
2016
- 2016-06-28 PH PH12016501268A patent/PH12016501268B1/en unknown
- 2016-06-28 SA SA516371427A patent/SA516371427B1/ar unknown
- 2016-06-28 CL CL2016001653A patent/CL2016001653A1/es unknown
- 2016-06-28 MA MA39155A patent/MA39155A1/fr unknown
- 2016-06-28 IL IL246498A patent/IL246498B/en active IP Right Grant
- 2016-06-29 US US15/196,318 patent/US10617638B2/en active Active
- 2016-12-01 HK HK16113732A patent/HK1225313A1/zh unknown
-
2018
- 2018-09-11 CY CY181100949T patent/CY1120668T1/el unknown
- 2018-09-28 HR HRP20181551TT patent/HRP20181551T1/hr unknown
-
2019
- 2019-07-25 JP JP2019136785A patent/JP6823118B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39155A1 (fr) | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol | |
| MA39154A1 (fr) | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol | |
| AR081540A1 (es) | Proceso para proveer particulas con cargas electroestaticas reducidas | |
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| RU2012142295A (ru) | Способ приготовления частиц носителя для сухих порошков для ингаляции | |
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| NZ600789A (en) | Aerosol formulation for copd | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| BR112022014228A2 (pt) | Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| MX2015015132A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
| CA3193038A1 (fr) | Formulation pharmaceutique pour inhalateur doseur pressurise | |
| JP2011500731A5 (fr) | ||
| JP2014527056A5 (fr) | ||
| CO7310521A2 (es) | Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo | |
| BR112022012361A2 (pt) | Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada | |
| TH171992A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| ZA202108150B (en) | An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate | |
| TH171993A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| PL432374A1 (pl) | Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa | |
| TR201716233A2 (tr) | Solunum yolları hastalıklarının tedavisi için birden fazla etken madde içeren farmasötik bileşim. | |
| TR201714893A1 (tr) | Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi. | |
| TH113758B (th) | องค์ประกอบเชิงเภสัชกรรมสำหรับการให้ยาโดยการรับประทาน |